Clinical Trial Update: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial is evaluating whether de-escalating the duration of maintenance immunotherapy benefits patients with stage IV non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Metastatic NSCLC | Phase 2, Phase 3 | Status: RECRUITING